Function, oligomerization, and conformation of tumor-associated p53 proteins with mutated C-terminus

Journal of Cellular Biochemistry

Volumn 76, Issue 4, 2000, Pages 572-584

  Atz, Judith ^a   Wagner, Peter ^a   Roemer, Klaus ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Apoptosis; Li Fraumeni syndrome; Tetramerization; Transactivation

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; GENE REPRESSION; HUMAN; HUMAN CELL; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DNA BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION;

ANTIBODIES; APOPTOSIS; CALPAIN; CENTRIFUGATION, DENSITY GRADIENT; DNA-BINDING PROTEINS; EPITOPES; GENES, REPORTER; HUMANS; MUTATION; PROTEIN CONFORMATION; REPRESSOR PROTEINS; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033973807     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(20000315)76:4<572::AID-JCB6>3.0.CO;2-6     Document Type: Article

References (42)

1. Attardi LD, Lowe SW, Brugarolas J, Jacks T. 1996. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J 15:3693-3701.
2. Chene P. 1999. p53 mutants without a functional tetramerization domain are not oncogenic. J Mol Biol 286:1269-1274.
3. Clore GM, Omichinski JG, Sakaguchi K, Zambrano N, Sakamoto H, Appella E, Gronenborg A. 1994. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 265:386-391.
4. Clore GM, Ernst J, Clubb R, Omichinski JG, Kennedy WMP, Sakaguchi K, Appella E, Gronenborg A. 1995. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nature Struct Biol 2:321-333.
5. Crook T, Marston NJ, Sara EA, Vousden KH. 1994. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79:817-827.
6. Davison TS, Yin P, Nie E, Kay C, Arrowsmith CH. 1998. Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene 17:651-656.
7. Gottlieb TM, Oren M. 1996. p53 in growth control and neoplasia. Biochim Biophys Acta 1287:77-102.
8. Gu W, Roeder RG. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606.
9. Hainaut P, Rolley N, Davies M, Milner J. 1995. Modulation by copper of p53 conformation and sequence-specific DNA binding: role for Cu(II)/Cu(I) redox mechanism. Oncogene 10:27-32.
10. Hall AR, Milner J. 1995. Structural and kinetic analysis of p53-DNA complexes and comparison of human and murine p53. Oncogene 10:561-567.
11. Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
12. Hollstein M, Shimer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC. 1996. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 24:141-146.
13. Hupp TR, Meek DW, Midgley CA, Lane DP. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875-886.
14. Hupp TR, Meek DW, Midgley CA, Lane DP. 1993. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res 21:3167-3174.
15. Ishioka C, Englert C, Shimada A, Osada M, Jia J-Q, Suzuki T, Gamo M, Kanamura R. 1997. Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells. Biochem Biophys Res Commun 232:54-60.
16. Jayaraman L, Freulich E, Prives C. 1997. Functional dissection of p53 tumor suppressor protein. Methods Enzymol 283:245-256.
17. Jeffrey PD, Gorina S, Pavletich NP. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 Angstroms. Science 267:1498-1502.
18. Kubbutat MHG, Jones SN, Vousden KH. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
19. Lee W, Harvey TS, Yin Y, Yau P, Litchfield D, Arrowsmith CH. 1994. Solution structure of the tetrameric minimum transforming domain of p53. Nature Struct Biol 1:877-890.
20. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
21. Liu Z, Hsu H, Goeddel DV, Karin M. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-κB activation prevents cell death. Cell 87:565-576.
22. Lomax ME, Barnes DM, Gilchrist R, Picksley S, Varley JG, Camplejohn RS. 1997. Two functional assays employed to detect an unusual mutation in the oligomerization domain of p53 in a Li-Fraumeni-like family. Oncogene 14: 1869-1874.
23. Lomax ME, Barnes DM, Hupp TR, Picksley SM, Camplejohn RS. 1998. Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni-like family members. Oncogene 17:643-649.
24. Mateu MG, Fersht AR. 1998. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumor suppressor p53 tetramerization domain. EMBO J 17:2748-2758.
25. Murphy M, Hinman A, Levine AJ. 1996. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 10:2971-2980.
26. Pariat M, Carillo S, Molinari M, Salvat C, Debussche L, Bracco L, Milner J, Piechaczyk M. 1997. Proteolysis by calpains: a possible contribution to degradation of p53. Mol Cell Biol 17:2806-2815.
27. Pellegata NS, Cajot JF, Stanbridge EJ. 1995. The basic carboxy-terminal domain of human p53 is dispensable for both transcriptional regulation and inhibition of tumor cell growth. Oncogene 11:337-349.
28. Pietenpol JA, Tokino T, Thiagalingam S, El-Deiry WS, Kinzler KW, Vogelstein B. 1994. Sequence-specific translational activation is essential for growth suppression by p53. Proc Natl Acad Sci USA 91:1998-2002.
29. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. 1997. A model for p53-induced apoptosis. Nature 389:300-305.
30. Prives C. 1998. Signaling to p53: Breaking the MDM2-p53 circuit. Cell 95:5-8.
31. Roemer K, Mueller-Lantzsch N. 1996. p53 transactivation domain mutant Q22,S23 is impaired for repression of promoters and mediation of apoptosis. Oncogene 12:2069-2079.
32. Rollenhagen C, Chene P. 1998. Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain. Int J Cancer 78:372-376.
33. Ryan KM, Vousden KH. 1998. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol Cell Biol 18:3692-3698.
34. Sakamuro D, Sabbatini P, White E, Prendergast GC. 1997. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene 15:887-898.
35. Schneider E, Montenarh M, Wagner P. 1998. Regulation of CAK kinase activity by p53. Oncogene 17:2733-2741.
36. Shieh S-Y, Ikeda M, Taya Y, Prives C. 1997. DNA damage induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
37. 2-terminal domain of p53. Int J Cancer 71:858-866.
38. Varley JG, McGown G, Thorncroft M, Cochrane S, Morrison P, Woll P, Kelsey AM, Mitchell EL, Boyle J, Birch JM, Evans DG. 1996. A previously undescribed mutation within the tetramerization domain of TP53 in a family with Li-Fraumeni syndrome. Oncogene 12:2437-2442.
39. Wagner P, Fuchs A, Götz C, Nastainczyk W, Montenarh M. 1998. Fine mapping and regulation of the association of p53 with p34cdc2. Oncogene 16:105-111.
40. Wang Y, Reed M, Wang P, Stenger JE, Mayr G, Anderson ME, Schwedes JF, Tegtmeyer P. 1993. p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev 7:2575-2586.
41. Waterman JLF, Shenk JL, Halazonetis TD. 1995. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J 14:512-519.
42. Waterman MJF, Stavridi ES, Waterman JLF, Halazonetis TD. 1998. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nature Genet 19:175-178.